Systemic Leakage and Side Effects of Tumor Necrosis Factor α Administered Via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment
- 1 October 1995
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 130 (10) , 1079-1084
- https://doi.org/10.1001/archsurg.1995.01430100057012
Abstract
Background: The tolerated systemic dose of recombinant tumor necrosis factor α (rTNF-α) is very limited, since its administration leads to a severe septic shock—like condition. Its implementation in isolated limb perfusion (ILP) for metastatic melanoma or advanced soft-tissue sarcoma confined to the limb facilitates doses of rTNF-α 10 times higher than the systemic tolerated dose. However, with the traditional high flow rate used in ILP, systemic leakage and side effects are not eliminated. Objective: To determine if a lower perfusion flow rate would reduce leakage and consequently toxic effects. Methods: Isolated limb perfusion was performed for melanoma and soft-tissue sarcoma confined to the limb using a flow rate of 869 ±122 mL/min in nine patients (group 1) and a lower rate of 286±62 mL/min in six patients (group 2). Results: The systemic leakage rate was 12.5%±2.9% in group 1, compared with 2.3%±1.0% in group 2 (P=.003). Peak TNF-α levels were 29 000±2700 pg/mL in group 1, higher than 1580±1355 pg/mL in group 2 (P=.02). The tachycardia, hypotension, increased cardiac output, decreased systemic vascular resistance, bilirubinemia, elevation of liver enzyme levels, hypocholestrolemia, thrombocytopenia, and prolongation of prothrombin and partial thromboplastin times all observed in group 1 were significantly attenuated or eliminated in group 2. The limb Po2, Pco2, pH, and viability remained similar in both groups. Also, the tumor response rate remained high and was unaffected by the decrease in flow rate. Conclusions: Decreasing perfusion flow rate during ILP results in diminished leakage of TNF-α Consequently, the systemic hemodynamic, metabolic, and hematologic toxic effects are virtually abolished. (Arch Surg. 1995;130:1079-1084)Keywords
This publication has 6 references indexed in Scilit:
- Effects of cytokines on the contractility of cultured cardiac myocytesInternational Journal of Immunopharmacology, 1993
- Cytokine‐induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cellsFEBS Letters, 1993
- High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.Journal of Clinical Oncology, 1992
- Neutrophil Mac-1 and MEL-14 Adhesion Proteins Inversely Regulated by Chemotactic FactorsScience, 1989
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.Journal of Clinical Oncology, 1988
- Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude miceInternational Journal of Cancer, 1984